Skip to main content

Research Repository

Advanced Search

IMOGEN PARKER's Outputs (1)

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer (2023)
Journal Article
Williams, C. J. M., Elliott, F., Sapanara, N., Aghaei, F., Zhang, L., Muranyi, A., …Quirke, P. (2023). Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer. Clinical Cancer Research, 29(20), 4153-4165. https://doi.org/10.1158/1078-0432.CCR-23-0859

Purpose: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial data. Here, AREG/EREG IHC wa... Read More about Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer.